中国肺癌杂志2025，Vol.28Issue(10)：761-768,8.DOI:10.3779/j.issn.1009-3419.2025.101.17
肺淋巴上皮癌的免疫治疗进展
Progress in Immunotherapy for Pulmonary Lymphoepithelioma Carcinoma
Weizhen SUN 1Yuheng ZHOU 1Shoucheng FENG 1Yaobin LIN 1Nengqi LIN 1Hao LONG1
作者信息
- 1. Department of Thoracic Surgery,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangzhou 510000,China
- 折叠
摘要
Abstract
Pulmonary lymphoepithelioma carcinoma(PLEC),a rare non-small cell lung cancer subtype strongly associated with Epstein-Barr virus(EBV)infection,currently lacks a standardized treatment regimen.Conventional platinum-based systemic chemoradiotherapy remains the primary approach.In recent years,its distinctive pathological features and tumor immune microenvironment have established a compelling rationale for immune checkpoint inhibitors(ICIs).Clinical studies have demonstrated promising efficacy and acceptable safety of ICIs,both as monotherapy and in combination with chemotherapy,in patients with advanced and resectable PLEC.Neoadjuvant immunotherapy has also emerged as a viable strat-egy to downstage tumors and improve resectability in operable cases.However,the rarity of PLEC has limited the availability of large-scale prospective trials,and current evidence is predominantly derived from retrospective analyses.Key challenges,including predictive biomarkers,mechanisms of immunotherapy,and optimal combination strategies,remain to be addressed.This review systematically summarizes the current clinical evidence,molecular mechanisms,and immune microenvironment characteristics of PLEC,and discusses future research directions.关键词
肺淋巴上皮癌/免疫治疗/新辅助免疫治疗/化免联合治疗/肿瘤免疫微环境Key words
Pulmonary lymphoepithelioma carcinoma/Immunotherapy/Neoadjuvant immunotherapy/Immuno-chemotherapy/Tumor immune microenvironment引用本文复制引用
Weizhen SUN,Yuheng ZHOU,Shoucheng FENG,Yaobin LIN,Nengqi LIN,Hao LONG..肺淋巴上皮癌的免疫治疗进展[J].中国肺癌杂志,2025,28(10):761-768,8.
